PEDIATRICS Vol. 36 No. 1 July 1965, pp. 149
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by COTTON, E. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by COTTON, E. K.

The Use of Priscoline in the Treatment of the Hypoperfusion Syndrome

ERNEST K. COTTON M.D.1

1 Assistant Professor in Pediatrics, University of Colorado Medical Center, Denver, Colorado 80220

In line with the report on pulmonary hypoperfusion as a possible mechanism in the etiology of hyaline membrane disease, we have been carrying out studies on newly born infants with this disease in order to correct the diminished pulmonary blood flow.

We have used drug therapy on a total of 5 infants, and this has been associated with considerable normalizing in various abnormalities caused by the disease. We have first corrected acidosis when present, and then given tolazoline HC1 (Priscoline).




This article has been cited by other articles:


Home page
 PediatricsHome page
P. Nuntnarumit, S. B. Korones, W. Yang, and H. S. Bada
Efficacy and Safety of Tolazoline for Treatment of Severe Hypoxemia in Extremely Preterm Infants
Pediatrics, May 1, 2002; 109(5): 852 - 856.
[Abstract] [Full Text] [PDF]